JPMorgan Investment Management, I recently announced the acquisition of new stake in Morgan Stanley (NYSE:MS). The institutional investor has increased its shareholding in the Financial company by 4.82% to 39.41 million shares with purchase of 1.81 million shares. This fresh investment now brings its stake to 2.40% valued currently at $3.67 billion.
Currently, there are 1.63B common shares owned by the public and among those 1.26B shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 54 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 24 of these insider trades were purchases, accounting for 1,103,851 shares. Insider sales of the common stock occurred on 30 occasions, with total insider shares sold totaling 1,019,845 shares.
The top 3 mutual fund holders in Morgan Stanley are Vanguard Total Stock Market ETF, Vanguard 500 Index Fund, and SPDR S&P 500 ETF Trust. Vanguard Total Stock Market ETF owns 38.63 million shares of the company’s stock, all valued at over $3.6 billion. The company sold -0.31 million shares recently to bring their total holdings to about 2.35% of the shares outstanding. Vanguard 500 Index Fund sold -0.23 million shares to see its total holdings shrink to 30.86 million shares valued at over $2.88 billion and representing 1.88% of the shares outstanding. SPDR S&P 500 ETF Trust sold 84750.0 shares to bring its total holdings to over 15.47 million shares at a value of $1.44 billion. SPDR S&P 500 ETF Trust now owns shares totaling to 0.94% of the shares outstanding.
The company’s stock has a 5-day price change of -5.71% and 13.97% over the past three months. MS shares are trading -8.48% year to date (YTD), with the 12-month market performance down to -11.64% lower. It has a 12-month low price of $69.42 and touched a high of $100.99 over the same period. MS has an average intraday trading volume of 8.93 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -6.44%, 0.83%, and 1.02% respectively.
Institutional ownership of Morgan Stanley (NYSE: MS) shares accounts for 62.10% of the company’s 1.63B shares outstanding. Mutual fund holders own 28.90%, while other institutional holders and individual stakeholders account for 33.61% and 27.07% respectively.
It has a market capitalization of $140.07B and a beta (3y monthly) value of 1.44. The stock’s trailing 12-month PE ratio is 16.50, while the earnings-per-share (ttm) stands at $5.17. The company has a PEG of 2.06 and the debt-to-equity ratio at 2.83. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.62% over the week and 1.71% over the month.
Analysts forecast that Morgan Stanley (MS) will achieve an EPS of $Micron Technology, Inc. for the current quarter, $87.51 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $QuantumScape Corporation while analysts give the company a high EPS estimate of $MSCI Emerging Markets Index Fut. Comparatively, EPS for the current quarter was $MSCI China NTR Futures – ICUS – a year ago. Earnings per share for the fiscal year are expected to increase by 23.25%, and 14.33% over the next financial year. EPS should grow at an annualized rate of 8.00% over the next five years, compared to 1.83% over the past 5-year period.
Looking at the support for the MS, a number of firms have released research notes about the stock. Keefe Bruyette stated their Mkt Perform rating for the stock in a research note on January 17, 2024, with the firm’s price target at $102-$91.
